Does the media prefer CADL or TNXP?

In the previous week, Tonix Pharmaceuticals had 1 more articles in the media than Candel Therapeutics. MarketBeat recorded 2 mentions for Tonix Pharmaceuticals and 1 mentions for Candel Therapeutics. Candel Therapeutics' average media sentiment score of 0.71 beat Tonix Pharmaceuticals' score of 0.39 indicating that Candel Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Candel Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tonix Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to SLN or TNXP?

In the previous week, Silence Therapeutics and Silence Therapeutics both had 2 articles in the media. Tonix Pharmaceuticals' average media sentiment score of 0.39 beat Silence Therapeutics' score of 0.00 indicating that Tonix Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Silence Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tonix Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer TNXP or PHAR?

In the previous week, Pharming Group had 12 more articles in the media than Tonix Pharmaceuticals. MarketBeat recorded 14 mentions for Pharming Group and 2 mentions for Tonix Pharmaceuticals. Tonix Pharmaceuticals' average media sentiment score of 0.39 beat Pharming Group's score of 0.34 indicating that Tonix Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tonix Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pharming Group 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor DBVT or TNXP?

In the previous week, Tonix Pharmaceuticals had 1 more articles in the media than DBV Technologies. MarketBeat recorded 2 mentions for Tonix Pharmaceuticals and 1 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 1.11 beat Tonix Pharmaceuticals' score of 0.39 indicating that DBV Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DBV Technologies 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tonix Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer TNXP or ANNX?

In the previous week, Tonix Pharmaceuticals and Tonix Pharmaceuticals both had 2 articles in the media. Annexon's average media sentiment score of 0.49 beat Tonix Pharmaceuticals' score of 0.39 indicating that Annexon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tonix Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Annexon 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Tonix Pharmaceuticals (TNXP) Competitors

$10.87 -0.55 (-4.82%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$10.96 +0.09 (+0.78%)

As of 09/18/2026 07:34 PM Eastern

Compare

TNXP vs. CADL, SLN, PHAR, DBVT, and ANNX

Should you buy Tonix Pharmaceuticals stock or one of its competitors? Tonix Pharmaceuticals's main competitors and comparable companies include Candel Therapeutics (CADL), Silence Therapeutics (SLN), Pharming Group (PHAR), DBV Technologies (DBVT), and Annexon (ANNX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Tonix Pharmaceuticals compare to Candel Therapeutics?

Candel Therapeutics (NASDAQ:CADL) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.

Candel Therapeutics has higher earnings, but lower revenue than Tonix Pharmaceuticals. Candel Therapeutics is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18M	-$1.41	N/A
Tonix Pharmaceuticals	$13.11M	14.22	-$124.02M	-$12.94	N/A

Candel Therapeutics has a beta of -0.48, suggesting that its share price is 148% less volatile than the broader market. Comparatively, Tonix Pharmaceuticals has a beta of 1.74, suggesting that its share price is 74% more volatile than the broader market.

In the previous week, Tonix Pharmaceuticals had 1 more articles in the media than Candel Therapeutics. MarketBeat recorded 2 mentions for Tonix Pharmaceuticals and 1 mentions for Candel Therapeutics. Candel Therapeutics' average media sentiment score of 0.71 beat Tonix Pharmaceuticals' score of 0.39 indicating that Candel Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Candel Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tonix Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

13.9% of Candel Therapeutics shares are owned by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. 14.3% of Candel Therapeutics shares are owned by insiders. Comparatively, 2.0% of Tonix Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Candel Therapeutics currently has a consensus price target of $19.29, indicating a potential upside of 77.99%. Tonix Pharmaceuticals has a consensus price target of $24.50, indicating a potential upside of 125.39%. Given Tonix Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Tonix Pharmaceuticals is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00

Candel Therapeutics has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -548.64%. Tonix Pharmaceuticals' return on equity of -68.99% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-76.98%	-48.50%
Tonix Pharmaceuticals	-548.64%	-68.99%	-61.31%

Summary

Tonix Pharmaceuticals beats Candel Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Tonix Pharmaceuticals compare to Silence Therapeutics?

Silence Therapeutics (NASDAQ:SLN) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

Silence Therapeutics presently has a consensus price target of $53.50, indicating a potential upside of 338.52%. Tonix Pharmaceuticals has a consensus price target of $24.50, indicating a potential upside of 125.39%. Given Silence Therapeutics' higher probable upside, research analysts clearly believe Silence Therapeutics is more favorable than Tonix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00

98.7% of Silence Therapeutics shares are owned by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. 3.0% of Silence Therapeutics shares are owned by company insiders. Comparatively, 2.0% of Tonix Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Silence Therapeutics and Silence Therapeutics both had 2 articles in the media. Tonix Pharmaceuticals' average media sentiment score of 0.39 beat Silence Therapeutics' score of 0.00 indicating that Tonix Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Silence Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tonix Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Silence Therapeutics has higher earnings, but lower revenue than Tonix Pharmaceuticals. Silence Therapeutics is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	$560K	1,311.72	-$88.61M	-$1.28	N/A
Tonix Pharmaceuticals	$13.11M	14.22	-$124.02M	-$12.94	N/A

Silence Therapeutics has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market. Comparatively, Tonix Pharmaceuticals has a beta of 1.74, meaning that its stock price is 74% more volatile than the broader market.

Tonix Pharmaceuticals has a net margin of -548.64% compared to Silence Therapeutics' net margin of -8,943.86%. Tonix Pharmaceuticals' return on equity of -68.99% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	-8,943.86%	-106.94%	-47.99%
Tonix Pharmaceuticals	-548.64%	-68.99%	-61.31%

Summary

Silence Therapeutics and Tonix Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Tonix Pharmaceuticals compare to Pharming Group?

Tonix Pharmaceuticals (NASDAQ:TNXP) and Pharming Group (NASDAQ:PHAR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

Pharming Group has a net margin of 2.51% compared to Tonix Pharmaceuticals' net margin of -548.64%. Pharming Group's return on equity of 3.40% beat Tonix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tonix Pharmaceuticals	-548.64%	-68.99%	-61.31%
Pharming Group	2.51%	3.40%	1.90%

Tonix Pharmaceuticals has a beta of 1.74, indicating that its share price is 74% more volatile than the broader market. Comparatively, Pharming Group has a beta of 0.01, indicating that its share price is 99% less volatile than the broader market.

82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.0% of Pharming Group shares are owned by institutional investors. 2.0% of Tonix Pharmaceuticals shares are owned by insiders. Comparatively, 2.1% of Pharming Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Pharming Group has higher revenue and earnings than Tonix Pharmaceuticals. Tonix Pharmaceuticals is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tonix Pharmaceuticals	$13.11M	14.22	-$124.02M	-$12.94	N/A
Pharming Group	$376.13M	1.99	$2.85M	$0.12	87.92

Tonix Pharmaceuticals presently has a consensus price target of $24.50, indicating a potential upside of 125.39%. Pharming Group has a consensus price target of $38.67, indicating a potential upside of 266.51%. Given Pharming Group's higher possible upside, analysts clearly believe Pharming Group is more favorable than Tonix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Pharming Group had 12 more articles in the media than Tonix Pharmaceuticals. MarketBeat recorded 14 mentions for Pharming Group and 2 mentions for Tonix Pharmaceuticals. Tonix Pharmaceuticals' average media sentiment score of 0.39 beat Pharming Group's score of 0.34 indicating that Tonix Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tonix Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pharming Group	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Pharming Group beats Tonix Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Tonix Pharmaceuticals compare to DBV Technologies?

DBV Technologies (NASDAQ:DBVT) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

DBV Technologies presently has a consensus target price of $48.50, indicating a potential upside of 292.71%. Tonix Pharmaceuticals has a consensus target price of $24.50, indicating a potential upside of 125.39%. Given DBV Technologies' higher possible upside, analysts plainly believe DBV Technologies is more favorable than Tonix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Tonix Pharmaceuticals had 1 more articles in the media than DBV Technologies. MarketBeat recorded 2 mentions for Tonix Pharmaceuticals and 1 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 1.11 beat Tonix Pharmaceuticals' score of 0.39 indicating that DBV Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DBV Technologies	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tonix Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

DBV Technologies has a beta of -0.95, meaning that its stock price is 195% less volatile than the broader market. Comparatively, Tonix Pharmaceuticals has a beta of 1.74, meaning that its stock price is 74% more volatile than the broader market.

Tonix Pharmaceuticals has higher revenue and earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$5.64M	137.69	-$146.95M	-$3.51	N/A
Tonix Pharmaceuticals	$13.11M	14.22	-$124.02M	-$12.94	N/A

Tonix Pharmaceuticals has a net margin of -548.64% compared to DBV Technologies' net margin of -3,506.53%. Tonix Pharmaceuticals' return on equity of -68.99% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-3,506.53%	-119.33%	-84.43%
Tonix Pharmaceuticals	-548.64%	-68.99%	-61.31%

71.7% of DBV Technologies shares are held by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are held by institutional investors. 1.1% of DBV Technologies shares are held by insiders. Comparatively, 2.0% of Tonix Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Tonix Pharmaceuticals beats DBV Technologies on 12 of the 17 factors compared between the two stocks.

How does Tonix Pharmaceuticals compare to Annexon?

Tonix Pharmaceuticals (NASDAQ:TNXP) and Annexon (NASDAQ:ANNX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation.

82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. 2.0% of Tonix Pharmaceuticals shares are owned by company insiders. Comparatively, 10.3% of Annexon shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Tonix Pharmaceuticals has a beta of 1.74, suggesting that its share price is 74% more volatile than the broader market. Comparatively, Annexon has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market.

Annexon has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -548.64%. Tonix Pharmaceuticals' return on equity of -68.99% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tonix Pharmaceuticals	-548.64%	-68.99%	-61.31%
Annexon	N/A	-106.15%	-79.82%

Tonix Pharmaceuticals has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tonix Pharmaceuticals	$13.11M	14.22	-$124.02M	-$12.94	N/A
Annexon	N/A	N/A	-$206.69M	-$1.16	N/A

Tonix Pharmaceuticals currently has a consensus target price of $24.50, indicating a potential upside of 125.39%. Annexon has a consensus target price of $15.14, indicating a potential upside of 257.99%. Given Annexon's higher probable upside, analysts plainly believe Annexon is more favorable than Tonix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00
Annexon	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Tonix Pharmaceuticals and Tonix Pharmaceuticals both had 2 articles in the media. Annexon's average media sentiment score of 0.49 beat Tonix Pharmaceuticals' score of 0.39 indicating that Annexon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tonix Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Annexon	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Tonix Pharmaceuticals beats Annexon on 9 of the 15 factors compared between the two stocks.

Get Tonix Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TNXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TNXP vs. The Competition

Export

Metric	Tonix Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$186.43M	$3.90B	$7.24B	$13.19B
Dividend Yield	N/A	3.64%	2.57%	12.81%
P/E Ratio	-0.84	14.23	274.93	25.38
Price / Sales	14.22	1,419.61	646.01	89.45
Price / Cash	N/A	108.90	76.25	51.42
Price / Book	0.57	15.45	10.46	6.33
Net Income	-$124.02M	-$22.86M	$3.49B	$358.33M
7 Day Performance	-8.42%	-1.21%	0.59%	1.12%
1 Month Performance	-14.61%	-4.42%	-2.01%	-2.67%
1 Year Performance	-58.19%	37.81%	18.09%	6.01%

Tonix Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TNXP Tonix Pharmaceuticals	4.145 of 5 stars	$10.87 -4.8%	$24.50 +125.4%	-61.7%	$186.43M	$13.11M	N/A	142	High Trading Volume
CADL Candel Therapeutics	3.3095 of 5 stars	$10.44 -7.9%	$19.29 +84.8%	+119.3%	$799.79M	N/A	N/A	60
SLN Silence Therapeutics	2.3286 of 5 stars	$13.18 -1.0%	$53.50 +305.9%	+142.5%	$794.47M	$560K	N/A	100	Positive News
PHAR Pharming Group	4.1576 of 5 stars	$10.91 +0.9%	$38.67 +254.4%	-25.0%	$772.21M	$376.13M	90.92	280	News Coverage Analyst Revision
DBVT DBV Technologies	3.4402 of 5 stars	$12.06 -7.0%	$48.50 +302.3%	+28.8%	$761.16M	$5.64M	N/A	80	Positive News High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TNXP) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tonix Pharmaceuticals (TNXP) Competitors

TNXP vs. CADL, SLN, PHAR, DBVT, and ANNX

How does Tonix Pharmaceuticals compare to Candel Therapeutics?

Summary

How does Tonix Pharmaceuticals compare to Silence Therapeutics?

Summary

How does Tonix Pharmaceuticals compare to Pharming Group?

Summary

How does Tonix Pharmaceuticals compare to DBV Technologies?

Summary

How does Tonix Pharmaceuticals compare to Annexon?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNXP vs. The Competition

Tonix Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tonix Pharmaceuticals (TNXP) Competitors

TNXP vs. CADL, SLN, PHAR, DBVT, and ANNX

How does Tonix Pharmaceuticals compare to Candel Therapeutics?

Which has stronger earnings and valuation, CADL or TNXP?

Which has more risk & volatility, CADL or TNXP?

Does the media prefer CADL or TNXP?

Do institutionals & insiders believe in CADL or TNXP?

Do analysts recommend CADL or TNXP?

Is CADL or TNXP more profitable?

Summary

How does Tonix Pharmaceuticals compare to Silence Therapeutics?

Do analysts prefer SLN or TNXP?

Do insiders and institutionals believe in SLN or TNXP?

Does the media refer more to SLN or TNXP?

Which has better earnings and valuation, SLN or TNXP?

Which has more volatility & risk, SLN or TNXP?

Is SLN or TNXP more profitable?

Summary

How does Tonix Pharmaceuticals compare to Pharming Group?

Is TNXP or PHAR more profitable?

Which has more risk & volatility, TNXP or PHAR?

Do institutionals and insiders believe in TNXP or PHAR?

Which has preferable valuation & earnings, TNXP or PHAR?

Do analysts prefer TNXP or PHAR?

Does the media prefer TNXP or PHAR?

Summary

How does Tonix Pharmaceuticals compare to DBV Technologies?

Do analysts recommend DBVT or TNXP?

Does the media favor DBVT or TNXP?

Which has more risk and volatility, DBVT or TNXP?

Which has stronger earnings and valuation, DBVT or TNXP?

Is DBVT or TNXP more profitable?

Do institutionals and insiders have more ownership in DBVT or TNXP?

Summary

How does Tonix Pharmaceuticals compare to Annexon?

Do institutionals and insiders believe in TNXP or ANNX?

Which has more volatility & risk, TNXP or ANNX?

Is TNXP or ANNX more profitable?

Which has stronger earnings & valuation, TNXP or ANNX?

Do analysts prefer TNXP or ANNX?

Does the media prefer TNXP or ANNX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNXP vs. The Competition

Tonix Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools